Mirum Pharmaceuticals, Inc. - common stock — Filings & Documents (NASDAQ:MIRM) — Page 12 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2019

Current report, Q3 FY2019

Mirum Pharmaceuticals, Inc. current report, Q3 FY2019

Quarterly report, Q2 FY2019

Mirum Pharmaceuticals, Inc. quarterly report, Q2 FY2019

1
...
5
6
7
8
9
10
11
12

News

12 Health Care Stocks Moving In Monday's Pre-Market Session

Mirum Pharmaceuticals' Phase 3 EXPAND Study Evaluating LIVMARLI Meets Primary Endpoint, Achieves Statistical Significance Across All Secondary Endpoints

What to Expect From Incyte’s Next Quarterly Earnings Report

RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

Citigroup Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $160

Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV

Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $130

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Transcript

HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Raises Price Target to $195

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow (NASDAQ:MIRM) 2026-09-28

Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment